Navidea biopharmaceuticals announces adoption of plan designed to protect nols and other tax assets, closing of bridge loan financing, and business update q&a series

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its board of directors has adopted a section 382 rights agreement that is designed to protect the availability of the company's net operating loss carryforwards (“nols”) and other tax assets (“section 382 rights plan”), and that it has entered into a stock exchang
NAVB Ratings Summary
NAVB Quant Ranking